Matica Biotechnology has announced a strategic partnerships with Treovir that aims to advance innovative therapies for pediatric patients with brain and other neurological cancers. Matica Bio will provide GMP manufacturing for clinical supplies.
Treovir, a biotechnology company developing oncolytic immunotherapies, will partner with Matica Bio on its G207 HSV-based oncolytic therapy for treating glioblastoma and other brain tumors in children. The therapy is currently in Phase 2 clinical trials and could ultimately provide a treatment option for children in this critically underserved therapeutic area. “Finding a CDMO partner who truly understands our mission and works alongside us as an extension of our team is essential for successful drug development,” said Michael Christini, CEO of Treovir. “We are collaborating with Matica Bio on process optimization and GMP clinical production for G207 and we look forward to advancing this promising therapy for pediatric brain tumors with Matica Bio playing a key role.”
Matica Bio is committed to leveraging its expertise in gene therapy development and manufacturing to support the creation of treatment that address the unique challenges faced by children with rare diseases.
“We are thrilled to partner with Treovir in this important effort,” said Paul Kim, CEO of Matica Bio. “Pediatric rare diseases represent an area of critical need, and Matica Bio is proud to contribute to the mission of improving the lives of these children. Our cutting-edge facilities and advanced manufacturing technologies provide the ideal foundation to help bring these life-changing therapies to market.”